Leveraging Label-Free Digital Imaging to Enable Rapid On-Site Evaluation (ROSE) During Thyroid Biopsy Procedures

项目摘要/摘要 Pathware正在开发生物光学™，这是一个在护理点分析活检样本的成像平台。这个 系统将快速数字化未染色的活检样本，并利用计算机辅助检测/诊断来实现 由病理学家进行快速有效的评估。医疗点诊断的典型障碍可通过以下方式克服 将新型计算显微镜与AI(人工智能)算法相结合，指导现场或远程 把病理学家带到临床感兴趣的区域。这项拟议的研究的广泛、长期目标是使真正的- 在护理点对病理样本进行时间诊断。 甲状腺结节的发病率很高，通过细针吸取(FNA)活检进行评估通常是一种 诊断流程中不可或缺的一步。活检样本经常不足以诊断，导致 重复活组织检查或不必要的手术切除。样本充分性的快速现场评估(ROSE)是 非常适合病人护理，因为它通过在 护理点。尽管活检不足的发生率很高，但只有不到25%的甲状腺接受了ROSE。 由于财务和操作障碍，包括病理学家的可用性，活组织检查程序。海流 ROSE的替代品(远程病理学、机器人显微镜和实时流显微镜)受到障碍的困扰 由于染色样品的要求、技术挑战和法规限制而无法采用。艾-- 辅助性ROSE有可能克服这些障碍，并提供更高的护理标准。 该项目的近期目标是：1)展示未染色甲状腺的非破坏性成像。 用一种新的显微镜设备进行细胞学涂片，2)为将来对获取的图像训练人工智能算法 玫瑰充分性评估的计算机辅助检测算法的开发。

Project Summary/Abstract Pathware is developing Bioptic™, an imaging platform to analyze biopsy samples at the point-of-care. The system will rapidly digitize unstained biopsy samples and utilize computer-aided detection/diagnostics to enable quick and efficient evaluations by pathologists. Typical barriers to point-of-care diagnostics are overcome by combining novel computational microscopy with AI (Artificial Intelligence) algorithms to direct on-site or remote pathologists to regions of clinical interest. This proposed research's broad, long-term objective is to enable real- time diagnostics of pathology samples at the point-of-care. Thyroid nodules have a high incidence rate, and assessment via fine-needle aspiration (FNA) biopsy is often an integral step in the diagnostic pipeline. The biopsy samples are frequently inadequate for diagnosis resulting in repeat biopsies or unnecessary surgical resections. Rapid On-Site Evaluation (ROSE) for sample adequacy is ideal for patient care, because it mitigates the risk of inadequate samples by verifying diagnostic quality at the point-of-care. Despite the high incidence of inadequate biopsies, ROSE is performed in less than 25% of thyroid biopsy procedures due to financial and operational barriers, including pathologist availability. The current alternatives to ROSE (telepathology, robotic microscopy, and live-streaming microscopy) are plagued by barriers to adoption due to the requirement of staining samples, technical challenges, and regulatory limitations. AI- assisted ROSE has the potential to overcome these barriers and provide a superior standard-of-care. The immediate goals of the proposed project are to 1) demonstrate non-destructive imaging of unstained thyroid cytology smears with a novel microscopy modality and 2) train AI algorithms on the acquired images for future development of computer-aided detection algorithms for ROSE adequacy assessments.